Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Ustekinumab biosimilar shows clinical similarity to reference drug for plaque psoriasis
A phase III study presented at EADV 2023 demonstrated the similarity between SB17, a human monoclonal antibody and proposed ustekinumab biosimilar, and reference ustekinumab for the treatment of moderate-to-severe plaque psoriasis.
Ustekinumab biosimilar shows clinical similarity to reference drug for plaque psoriasis
19 Oct 2023
Age, sex, prior complaints predict GI symptoms in adults with new-onset diabetes
Nearly half of individuals with a newly diagnosed type 1 (T1D) or type 2 diabetes (T2D) suffer from gastrointestinal (GI) symptoms, according to a study presented at EASD 2023. These GI adverse events that are associated with glucose-lowering medications occur more frequently among those with already existing GI symptoms prior to treatment initiation.
Age, sex, prior complaints predict GI symptoms in adults with new-onset diabetes
18 Oct 2023
Does early antihypertensive treatment prevent death in stroke patients?
Early antihypertensive treatment appears to have no significant benefits in terms of dependency or death at 90 days among patients with mild-to-moderate acute ischaemic stroke and systolic blood pressure (SBP) between 140 and <220 mm Hg, reports a study.
Does early antihypertensive treatment prevent death in stroke patients?
17 Oct 2023
ARCADIA trials: A win for nemolizumab in atopic dermatitis
In the phase III ARCADIA 1 and 2 trials, the investigational, first-in-class interleukin-31-Rα antagonist nemolizumab delivered early, rapid, and sustained improvements in the core signs and symptoms of atopic dermatitis (AD) in patients with moderate-to-severe disease.
ARCADIA trials: A win for nemolizumab in atopic dermatitis
17 Oct 2023
Dapagliflozin cuts HbA1c in paediatric T2D
Dapagliflozin reduced HbA1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes (T2D), while saxagliptin showed no significant reduction vs placebo in the phase III T2NOW trial presented at EASD 2023.